# EP300
## Overview
Mutations in EP300 are significant contributors to the pathogenesis and progression of B-cell lymphomas such as DLBCL and FL. These mutations impair histone acetylation, disrupt epigenetic gene regulation. EP300 mutations typically result in the loss of its HAT domain, which is crucial for acetylating histones and non-histone proteins.<sup>1,2</sup> 

## Relevance tier by entity

|Entity|Tier|Description                           |
|:------:|:----:|--------------------------------------|
|BL    |2   |relevance in BL not firmly established|
|DLBCL |1   |high-confidence DLBCL gene            |
|FL    |1   |high-confidence FL gene               |

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source               |frequency (%)|
|:------:|:---------------------:|:-------------:|
|BL    |GAMBL genomes+capture| 4.62        |
|BL    |Thomas cohort        | 4.20        |
|BL    |Panea cohort         | 7.90        |
|DLBCL |GAMBL genomes        |11.85        |
|DLBCL |Schmitz cohort       | 9.79        |
|DLBCL |Reddy cohort         | 7.11        |
|DLBCL |Chapuy cohort        | 8.12        |
|FL    |GAMBL genomes        |12.47        |

## Mutation pattern and selective pressure estimates

|Entity|aSHM|Significant selection|dN/dS (missense)|dN/dS (nonsense)|
|:------:|:----:|:---------------------:|:----------------:|:----------------:|
|BL    |No  |No                   | 2.769          |3.550           |
|DLBCL |No  |No                   | 3.344          |7.980           |
|FL    |No  |Yes                  |15.586          |7.719           |



> [!NOTE]
> First described in DLBCL in 2011 by [Pasqualucci L](https://pubmed.ncbi.nlm.nih.gov/21390126). First described in FL in 2011 by [Morin RD](https://pubmed.ncbi.nlm.nih.gov/21796119)

 ## EP300 Hotspots

| Chromosome |Coordinate (hg19) | ref>alt | HGVSp | 
 | :---:| :---: | :--: | :---: |
|chr22|41566459|T>C|Y1446H|
|chr22|41566460|A>G|Y1446C|
|chr22|41566460|A>C|Y1446S|
|chr22|41566462|A>T|I1447F|
|chr22|41566466|T>G|F1448C|
|chr22|41566474|C>T|H1451Y|
|chr22|41566476|T>G|H1451Q|
|chr22|41566478 | C>T | P1452L |
|chr22|41566486|C>G|Q1455E|
|chr22|41566487|A>G|Q1455R|
|chr22|41566488|G>T|Q1455H|
|chr22|41566495|C>T|P1458S|
|chr22|41566495|C>A|P1458T|
|chr22|41566496|C>T|P1458L|
|chr22|41566511|T>C|L1463P|
|chr22|41566511|T>G|L1463R|
|chr22|41566519|T>G|W1466G|
|chr22|41566519|T>A|W1466R|
|chr22|41566519|T>C|W1466R|
|chr22|41566520|G>T|W1466L|
|chr22|41566521|G>C|W1466C|
|chr22| 41566522 | T>A | Y1467N |
|chr22| 41566522 | T>C | Y1467H |
|chr22| 41566522 | T>G | Y1467D |
|chr22| 41566523 | A>G | Y1467C |
|chr22| 41566523 | A>T | Y1467F |

View coding variants in ProteinPaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/EP300_protein.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/EP300_protein_hg38.html)

![image](images/proteinpaint/EP300_NM_001429.svg)

View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/EP300.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/EP300_hg38.html)

![image](images/proteinpaint/EP300.svg)

## References
1. *Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L., Lerach, S., Tang, H., Ma, J., Rossi, D., Chadburn, A., Murty, V., Mullighan, C., Gaidano, G., Rabad√°n, R., Brindle, P., & Dalla-Favera, R. (2010). Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature, 471, 189 - 195. https://doi.org/10.1038/nature09730.*

2. *Cerchietti, L., Hatzi, K., Caldas-Lopes, E., Yang, S., Figueroa, M., Morin, R., Hirst, M., Mendez, L., Shaknovich, R., Cole, P., Bhalla, K., Gascoyne, R., Marra, M., Chiosis, G., & Melnick, A. (2010). BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. The Journal of clinical investigation, 120 12, 4569-82 . https://doi.org/10.1172/JCI42869.* 
